| Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of … MA Thompson, MJ Mugavero, KR Amico, VA Cargill, LW Chang, R Gross, ... Annals of internal medicine 156 (11), 817-833, 2012 | 722 | 2012 |
| Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design SD Lawn, L Myer, C Orrell, LG Bekker, R Wood Aids 19 (18), 2141-2148, 2005 | 466 | 2005 |
| Adherence is not a barrier to successful antiretroviral therapy in South Africa C Orrell, DR Bangsberg, M Badri, R Wood Aids 17 (9), 1369-1375, 2003 | 465 | 2003 |
| Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ... New England Journal of Medicine 384 (11), 1003-1014, 2021 | 320 | 2021 |
| Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial I Sanne, C Orrell, MP Fox, F Conradie, P Ive, J Zeinecker, M Cornell, ... The Lancet 376 (9734), 33-40, 2010 | 303 | 2010 |
| Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation SD Lawn, L Myer, G Harling, C Orrell, LG Bekker, R Wood Clinical infectious diseases 43 (6), 770-776, 2006 | 295 | 2006 |
| Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality MWG Brinkhof, A Boulle, R Weigel, E Messou, C Mathers, C Orrell, ... PLoS medicine 6 (4), e1000066, 2009 | 248 | 2009 |
| Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non … ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, ... The Lancet 396 (10267), 1994-2005, 2020 | 234 | 2020 |
| Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa LG Bekker, L Myer, C Orrell, S Lawn, R Wood South African medical journal 96 (4), 315-320, 2006 | 217 | 2006 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 209 | 2018 |
| Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa K Kranzer, J Zeinecker, P Ginsberg, C Orrell, NN Kalawe, SD Lawn, ... PloS one 5 (11), e13801, 2010 | 198 | 2010 |
| Improving antiretroviral therapy adherence in resource‐limited settings at scale: a discussion of interventions and recommendations JE Haberer, L Sabin, KR Amico, C Orrell, O Galárraga, AC Tsai, ... African Journal of Reproduction and Gynaecological Endoscopy 20 (1), 2017 | 186 | 2017 |
| Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority … ENCORE1 Study Group The Lancet 383 (9927), 1474-1482, 2014 | 182 | 2014 |
| Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited C Orrell, G Harling, SD Lawn, R Kaplan, M McNally, LG Bekker, R Wood Antiviral therapy 12 (1), 83-88, 2007 | 173 | 2007 |
| Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort A Boulle, C Orrell, R Kaplan, G Van Cutsem, M McNally, K Hilderbrand, ... Antiviral therapy 12 (5), 753-760, 2007 | 167 | 2007 |
| Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared O Keiser, C Orrell, M Egger, R Wood, MWG Brinkhof, H Furrer, ... PLoS medicine 5 (7), e148, 2008 | 166 | 2008 |
| Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme SD Lawn, LG Bekker, L Myer, C Orrell, R Wood Aids 19 (17), 2050-2052, 2005 | 157 | 2005 |
| Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa MD Nglazi, SD Lawn, R Kaplan, K Kranzer, C Orrell, R Wood, LG Bekker JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (1), e1-e8, 2011 | 155 | 2011 |
| Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa SD Lawn, F Little, LG Bekker, R Kaplan, E Campbel, C Orrell, R Wood Aids 23 (3), 335-342, 2009 | 155 | 2009 |
| Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors K Kranzer, JJ Lewis, N Ford, J Zeinecker, C Orrell, SD Lawn, LG Bekker, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (3), e17-e23, 2010 | 146 | 2010 |
